Materials for the Administration of Human Genetic Resources
Release Date:
2023-03-30 16:57
I. Approval for the Collection of Human Genetic Resources in China
Application Form Template Download:
https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Collection_of_Audits.zip
II. Approval for the Preservation of China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Quality Assurance Template.doc
III. Approval for International Collaborative Scientific Research Involving China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/National_Collaborative_Science_and_Technology_Research_Accreditation.zip
IV. Approval for the Export of China’s Human Genetic Resources
Application Form Template Download:
https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Materials_Review.zip
V. Filing of International Collaborative Clinical Trials Involving China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/National Joint Testing Project Template.doc
VI. Filing for the External Provision or Open Access to Information on China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Information_Sheets_and_Folders.zip
VII. List of Materials to Be Submitted via the Online Filing System
1 Application Form (Attachment)
2. The business license or organizational code certificate, and the legal person certificate of this entity
3. Supporting documentation specifying the Chinese-side and foreign-side institutions
Application Form Template Download:
https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/ktwssbxttjclqd.docx
Related News
With the rapid advancement of cell and gene therapies, the industry is placing increasingly stringent demands on the performance, batch-to-batch consistency, and supply-chain reliability of cell-sorting reagents. At present, the domestic market for sorting magnetic beads remains dominated by imported brands, and their high cost of use and uncertain supply have become significant barriers to both research and industrialization in China.
Recently, Professor Huang He’s team at Zhejiang University published in the top oncology journal “…”. Nature Cancer 》published a research paper titled “Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.” This study is the first to reveal that Serum iron overload By elucidating the key mechanisms by which ferroptosis induces functional exhaustion of CAR‑T cells, we have proposed a targeted approach. ACSL4 Alternatively, a novel strategy involves using the ferroptosis inhibitor Fer-1 to enhance CAR-T cell persistence and antitumor efficacy.
Hycells’s Selected PBMC Reconstruction Data Presentation (Part 2)
HuPBMC model Due to its rapid establishment (3–4 weeks) and ease of use, it has been widely employed for in vivo efficacy evaluation in tumor immunotherapy. However, the conventional model suffers from a critical limitation: the randomness and uncertainty inherent in donor selection. The root of the problem lies not in the model itself, but in the “seed” cells—PBMCs—introduced into the system.
Hycells’s Selected PBMC Reconstruction Data Presentation (Part 1)
The humanized PBMC-CDX model is an essential tool for in vivo efficacy evaluation of tumor immunotherapy agents. However, significant inter‑donor variability exists in the engraftment efficiency, T‑cell subset differentiation, and the risk of graft‑versus‑host disease (GVHD) among different PBMC donors, which directly impacts model stability and the experimental window.
A Fresh Start, A New Beginning | Hycells’s Brand Identity Fully Reimagined
Every step forward is aimed at fulfilling our mission even more effectively.
Focused on peptide immunogenicity assessment, precisely empowering tumor neoantigens.
In the field of cancer immunotherapy, tumor neoantigen–specific T-cell responses serve as a key metric for assessing peptide immunogenicity. Leveraging its well-established in vitro assay platform, Hycells Biotechnology offers end-to-end services—ranging from initial screening of peptide immunogenicity and antigen‑specific T-cell expansion to validation of tumor cell‑killing activity—thereby supporting the efficient and reliable discovery and validation of neoantigens.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board